MedPath

Ranitidine

Generic Name
Ranitidine
Brand Names
Good Sense Acid Reducer, Wal-zan, Zantac
Drug Type
Small Molecule
Chemical Formula
C13H22N4O3S
CAS Number
66357-35-5
Unique Ingredient Identifier
884KT10YB7
Background

Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as cimetidine and famotidine. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion. Ranitidine is often referred to as Zantac, and is available in various forms, including tablet, injection, and effervescent tablet preparations.

The prevalence of GERD is thought to be 10-20% in western countries. Ranitidine has proven to be an effective treatment for relieving uncomfortable symptoms of gastric acid associated conditions and is therefore widely used in GERD and other gastric-acid related conditions.

Indication

This drug is used alone or with concomitant antacids for the following conditions: short-term treatment of active duodenal ulcer, treating gastric acid hypersecretion due to Zollinger-Ellison syndrome, systemic mastocytosis, and other conditions that may pathologically raise gastric acid levels. It also used in the short term treatment of active benign gastric ulcers and maintenance therapy of gastric ulcers at a reduced dose. In addition to the above, ranitidine can be used for the treatment of GERD symptoms, treatment of erosive esophagitis (endoscopically diagnosed) and the maintenance of gastric or duodenal ulcer healing.

Associated Conditions
Acid Aspiration Syndrome, Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastric hypersecretion, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Osteoarthritis (OA), Peptic Ulcer Disease, Rheumatoid Arthritis, Stress Ulcers, Zollinger-Ellison Syndrome, Active Duodenal ulcer, Benign gastric ulcer healing, Benign gastric ulcers, Duodenal ulcer healing, Post-operative peptic ulcer, Recurrent hemorrhage from bleeding ulcers
Clinical Trials
Related News

GSK's Pipeline Strengthens with Positive Phase III Trials, Anticipates Multiple Product Launches in 2025

• GSK reports strong Q3 sales and core operating profit growth, driven by specialty medicines offsetting lower vaccine sales, indicating portfolio resilience. • Eleven positive Phase III trials have been reported this year, bolstering GSK's pipeline and supporting confidence in 2024, 2026, and 2031 outlooks. • The company is planning for the launch of five major new products in 2025, including Blenrep, Depemokimab, Nucala for COPD, Gepotidacin, and a new meningitis vaccine (MenABCWY).

GSK Announces Q3 2024 Results: Specialty Medicines Drive Growth, Pipeline Strengthens

• GSK's Q3 2024 sales reached £8.0 billion, with a 2% CER increase, driven by strong performance in Specialty Medicines, offsetting lower Vaccines sales. • R&D progress includes EU approval for Arexvy in adults aged 50-59 and positive Phase III results for depemokimab in chronic rhinosinusitis with nasal polyps (CRSwNP). • The company confirms its 2024 guidance, projecting a 7-9% turnover growth and a 10-12% increase in core EPS, excluding COVID-19 solutions. • A Q3 2024 dividend of 15p per share has been declared, with expectations to declare a 60p per share dividend for the full year.

GSK's mRNA Influenza Vaccine Shows Promise in Phase II Trial, Advancing to Phase III

• GSK's mRNA seasonal influenza vaccine candidate met pre-defined success criteria in Phase II trials for both younger and older adults, demonstrating positive immune responses against influenza A and B strains. • The mRNA platform elicited strong overall antibody titers with an acceptable safety profile, supporting its potential as a next-generation influenza vaccine. • Based on the Phase II results, GSK plans to advance its mRNA influenza vaccine program into late-stage clinical development, aiming for a best-in-class vaccine. • The Phase II trial (NCT06431607) assessed the reactogenicity, safety, and immunogenicity of different dose levels of the vaccine in 500 healthy adults.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy